In the BioHarmony Drug Report Database

"Preview" Icon

Afatinib

Gilotrif, Giotrif (afatinib) is a small molecule pharmaceutical. Afatinib was first approved as Gilotrif on 2013-07-12. It is used to treat non-small-cell lung carcinoma and squamous cell carcinoma in the USA. It has been approved in Europe to treat non-small-cell lung carcinoma. The pharmaceutical is active against epidermal growth factor receptor. In addition, it is known to target receptor tyrosine-protein kinase erbB-2. Gilotrif’s patents are valid until 2030-07-05 (FDA).

 

Trade Name

 

Giotrif
 

Common Name

 

afatinib
 

ChEMBL ID

 

CHEMBL1173655
 

Indication

 

non-small-cell lung carcinoma, squamous cell carcinoma
 

Drug Class

 

Tyrosine kinase inhibitors

Image (chem structure or protein)

Afatinib structure rendering